Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Exp Clin Cancer Res ; 25(2): 145-60, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16918124

ABSTRACT

Transitional cell carcinoma of the bladder is a common tumor. While most patients presenting superficial disease can be expected to do well following treatment, still many patients will return to our office with muscle invasive and metastatic disease. Survival in advanced bladder cancer is less than 50%. Tumors of similar histologic grade and stage have variable behavior, suggesting that genetic alterations must be present to explain the diverse behavior of bladder cancer. It is hoped that through the study of the subtle genetic alterations in bladder cancer, important prognostic and therapeutic targets can be exploited. Many new diagnostic tests and gene therapy approaches rely on the identification and targeting of these unique genetic alterations. A review of literature published on the molecular genetics of bladder cancer from 1970 to the present was conducted. A variety of molecular genetic alterations have been identified in bladder cancer. Oncogenes (H-ras, erbB-2, EGFR, MDM2, C-MYC, CCND1), tumor suppressor genes (p53, Rb, p21, p27/KIP1, p16, PTEN, STK15, FHIT, FEZ1/LZTS1, bc10), telomerase, and methylation have all been studied in bladder cancer. Several have proven to be potentially useful clinical targets in the prognosis and therapy of bladder cancer such as staining for p53 and gene therapy strategies such as p53 and fez1. Clinical trials targeting HER2/neu and the EGFR pathways are underway. The UroVysion bladder cancer assay relies on FISH to detect genetic alterations in this disease. Continuing identification of the molecular genetic alterations in bladder cancer will enhance future diagnostic and therapeutic approaches to bladder cancer. Capitalizing on these alterations will allow early detection, providing important prognostic information and unique targets for gene therapy and other therapeutic approaches.


Subject(s)
Biomarkers, Tumor/genetics , Genetic Therapy , Urinary Bladder Neoplasms/genetics , Animals , Humans , Molecular Biology , Urinary Bladder Neoplasms/diagnosis , Urinary Bladder Neoplasms/therapy
2.
Reproduction ; 132(3): 423-34, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16940283

ABSTRACT

Centrin is an evolutionarily conserved 20 kDa, Ca+2-binding, calmodulin-related protein associated with centrioles and basal bodies of phylogenetically diverse eukaryotic cells. Earlier studies have shown that residual centrosomes of non-rodent mammalian spermatozoa retain centrin and, in theory, could contribute this protein for the reconstruction of the zygotic centrosome after fertilization. The present work shows that CEN2 and CEN3 mRNA were detected in germinal vesicle-stage (GV) oocytes, MII oocytes, and pre-implantation embryos from the two-cell through the blastocyst stage, but not in spermatozoa. Boar ejaculated spermatozoa possess centrin as revealed by immunofluorescence microscopy and western blotting. Immature, GV oocytes possess speckles of centrin particles in the perinuclear area, visualized by immunofluorescence microscopy and exhibit a 19 kDa band revealed by western blotting. Mature MII stage oocytes lacked centrin that could be detected by immunofluorescence or western blotting. The sperm centrin was lost in zygotes after in vitro fertilization. It was not detectable in embryos by immunofluorescence microscopy until the late blastocyst stage. Embryonic centrin first appeared as fine speckles in the perinuclear area of some interphase blastocyst cells and as putative centrosomes of the spindle poles of dividing cells. The cells of the hatched blastocysts developed centrin spots comparable with those of the cultured cells. Some blastomeres displayed undefined curved plate-like centrin-labeled structures. Anti-centrin antibody labeled interphase centrosomes of cultured pig embryonic fibroblast cells as distinct spots in the juxtanuclear area. Enucleated pig oocytes reconstructed by electrofusion with pig fibroblasts displayed centrin of the donor cell during the early stages of nuclear decondensation but became undetectable in the late pronuclear or cleavage stages. These observations suggest that porcine zygotes and pre-blastocyst embryonic cells lack centrin and do not retain exogenously incorporated centrin. The early embryonic centrosomes function without centrin. Centrin in the blastocyst stage embryos is likely a result of de novo synthesis at the onset of differentiation of the pluripotent blastomeres.


Subject(s)
Blastocyst/chemistry , Calcium-Binding Proteins/analysis , Chromosomal Proteins, Non-Histone/analysis , Embryonic Development/physiology , Swine/physiology , Zygote/chemistry , Animals , Blotting, Western/methods , Calcium-Binding Proteins/genetics , Cells, Cultured , Centrosome/metabolism , Chromosomal Proteins, Non-Histone/genetics , Cloning, Organism , Female , Fluorescent Antibody Technique , Male , Microscopy, Fluorescence , Oocytes/chemistry , Oocytes/metabolism , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Sperm Injections, Intracytoplasmic , Spermatozoa/chemistry , Spermatozoa/metabolism
3.
Adv Med Sci ; 51 Suppl 1: 114-8, 2006.
Article in English | MEDLINE | ID: mdl-17458073

ABSTRACT

UNLABELLED: Regular supply of fluoride ions to the oral environment is one of the prophylactic actions against dental caries. Fluorides, whose exogenous action combines with saliva properties, condition the anticariogenic effect. Fluoride ions exhibit high chemical activity, can alter the oral environment parameters and inhibit the activity of enzymes. PURPOSE: In the current study, the effect of fluoride preparations used in professional caries prophylaxis on chosen saliva parameters was studied. The levels of pH and fluoride ions, and the activity of cathepsin D in human saliva were determined. MATERIAL AND METHODS: Material for analysis contained resting mixed saliva collected before and 1, 4 and 24 hours after the application of Duraphat, Elmex Gel, Fluor Protector, Fluormex Gel and Fluoro-Gel. RESULTS: The fluoride-containing preparations inhibited the activity of cathepsin D in the way depending on the time that had passed since the application and altered the pH level of human saliva.


Subject(s)
Cathepsin D/antagonists & inhibitors , Fluorides, Topical/pharmacology , Saliva/drug effects , Cathepsin D/analysis , Humans , Hydrogen-Ion Concentration/drug effects , Saliva/chemistry , Saliva/enzymology
SELECTION OF CITATIONS
SEARCH DETAIL
...